Pulmonary metastasectomy is indicated for selected patients with metastatic colorectal cancer. A 43-year-old woman presented with solitary pulmonary metastasis from descending colon cancer and pulmonary metastasectomy was performed because of absence of any other active metastasis as well as normal serum carcinoembryonic antigen value. However, she died due to early development of nodal and bone metastases within 6 months after thoracotomy. The presence of circulating tumor cells (CTCs) in the peripheral blood (6 CTCs/7.5 ml) was the only factor to predict such a poor prognosis, suggesting that the CTC test is useful in selecting patients for pulmonary metastasectomy.
Introduction
Surgery for pulmonary metastases from colorectal cancer (CRC) is indicated for selected patients who meet conventional criteria as follows: (1) the metastases seem to be technically resectable; (2) the general and functional risks are tolerable; (3) the primary tumor is controlled; (4) no active extrathoracic lesions are detected [1, 2] . However, the optimal criteria to identify patients for whom pulmonary metastasectomy may provide a modest survival benefit remain controversial, although a number of studies have revealed potential prognostic factors such as serum carcinoembryonic antigen (CEA) level [3, 4] . Circulating tumor cells (CTCs) are potential surrogates of distant metastasis, and their presence is a novel and promising biomarker in the diagnosis and therapy of a variety of malignant tumors [5] [6] [7] [8] . The CTC test using the CellSearch system (Velidex, LLC, North Raritan, N.J., USA), an automated quantitative CTC detection system, has been approved for monitoring of blood from metastatic CRC patients by the Food and Drug Administration in the USA. Here, we present the case of a woman with solitary pulmonary metastasis from CRC who died of tumor recurrence within 6 months after thoracotomy; the presence of CTCs in the peripheral blood sampled before thoracotomy was the only factor to predict such a poor prognosis.
Case Report
A 43-year-old Japanese woman with suspicion of a solitary pulmonary metastasis presented in September 2009, after a series of therapies for colon cancer as follows: (1) fig. 1a, b) . Serum CEA level was normal (2.2 ng/ml), and pulmonary metastasectomy was performed with the establishment of pathological diagnosis of pulmonary metastasis. A 7.5-ml sample of peripheral blood taken just before thoracotomy was used for the CTC test, which revealed the presence of CTCs (6 CTCs/7.5 ml). Multiple nodal and bone metastases were found 1 month after thoracotomy ( fig. 2a) , and developed ( fig. 2b ) in spite of received systemic chemotherapy. Finally, the patient died of tumor progression 172 days after thoracotomy.
Discussion
The present case showed a very poor prognosis of only 6 months' survival after pulmonary metastasectomy due to early development of nodal and bone metastases, although the case met the traditional selection criteria for pulmonary metastasectomy [1, 2] . In addition, the present case had a normal serum CEA level, solitary pulmonary metastasis and no intrathoracic nodal metastasis, which are favorable prognostic factors revealed in previous studies [9] [10] [11] . Thus, the only factor to predict a poor prognosis in the case was her elevated CTC count (6 CTCs/7.5 ml peripheral blood), which was consistent with a study showing that an elevated CTC count (3 or more CTCs/7.5 ml) was an independent and significant prognostic factor for shorter survival [7] . Thus, the present case suggests that patients with an elevated CTC count may not be good candidates for pulmonary metastasectomy even when the case meets the conventional selection criteria. A prospective study, to assess the clinical value of the CTC test in selecting patients for pulmonary metastasectomy, is warranted. Fig. 2 . Multiple nodal and bone metastases were found by PET-CT scan taken 1 month after thoracotomy (a), and they aggressively developed 4 months after thoracotomy (b).
